ID   VAL
AC   CVCL_1819
DR   CLO; CLO_0037067
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473489
DR   cancercelllines; CVCL_1819
DR   Cell_Model_Passport; SIDM00416
DR   Cosmic; 1086346
DR   Cosmic; 1517631
DR   Cosmic; 1541908
DR   Cosmic; 2276320
DR   Cosmic; 2297002
DR   Cosmic; 2590022
DR   Cosmic-CLP; 1331048
DR   DepMap; ACH-001703
DR   DSMZ; ACC-586
DR   DSMZCellDive; ACC-586
DR   EGA; EGAS00001000978
DR   GDSC; 1331048
DR   GEO; GSM115973
DR   GEO; GSM201349
DR   GEO; GSM1035309
DR   GEO; GSM1670570
DR   LINCS_LDP; LCL-1915
DR   Lonza; 1237
DR   PharmacoDB; VAL_1652_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1819
DR   Wikidata; Q54992842
RX   PubMed=8220427;
RX   PubMed=8558920;
RX   PubMed=16960149;
RX   PubMed=19358282;
RX   PubMed=20454443;
RX   PubMed=26727417;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31160637;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: ~50-70 hours (DSMZ=ACC-586).
CC   HLA typing: A*02:01:01,68:01:01; B*15:01:01,15:01:01; C*03:03:01,03:03:01; DPA1*02:02:02,02:01:02; DPB1*19:01,19:01; DQA1*01:03:01,01:03:01; DQB1*06:03:01,06:03:01; DRA*01:01:01,01:01:01; DRB1*13:01:01,13:01:01 (DSMZCellDive=ACC-586).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.47%; South Asian=2.83%; European, North=64.59%; European, South=32.11% (PubMed=30894373).
CC   Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10,14
ST   D16S539: 9,13
ST   D18S51: 14,16,17 (DSMZ)
ST   D18S51: 16,17 (DepMap)
ST   D19S433: 13,14
ST   D21S11: 27,30
ST   D2S1338: 20,23
ST   D3S1358: 17,19
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 11,12
ST   FGA: 22,24
ST   Penta D: 9
ST   Penta E: 7
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 14,15
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   PubMed=8220427; DOI=10.1038/ng0993-66;
RA   Kerckaert J.-P., Deweindt C., Tilly H., Quief S., Lecocq G.,
RA   Bastard C.;
RT   "LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring
RT   chromosome 3q27 translocations in human lymphomas.";
RL   Nat. Genet. 5:66-70(1993).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//